Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one randomized controlled trial. ^[1]
• In the QUantum Immuno-oncology Lifelong Trial (QUILT)-3.032 study, N-803 (nogapendekin alfa inbakicept) combined with Bacillus Calmette-Guérin (BCG) induced durable complete responses in patients with BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC).
• Patient-reported outcomes, including physical function (PF) and global health (GH) scores, remained stable from baseline through the 24-month follow-up for both Cohort A (patients with carcinoma in situ with or without Ta/T1 disease) and Cohort B (patients with high-grade Ta/T1 papillary disease).
• Subgroup analysis revealed that in Cohort A, patients with a complete response had higher PF scores at month 6 (P = .0659), while those with more than three prior bladder tumor resections showed lower GH scores at month 12 (P = .0729). In Cohort B, baseline disease type was linked to PF scores (P = .0738), and race significantly influenced GH scores at month 6 (P = .0478).
• There is no safety information available in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.